| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 9
| Issue : 2 | Page : 127-131 |
|
|
Mucormycosis in COVID-19 patients: A tertiary care experience
Sarandeep Singh Puri1, Jyoti Mishra1, Monal Trisal1, Ashish Kumar Mandal1, Suparna Dubey2
1 Department of Pathology, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India
2 Department of Pathology, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, India
Correspondence Address:
Dr. Ashish Kumar Mandal
Department of Pathology, School of Medical Sciences and Research, Sharda University, Plot No. 32-34, Knowledge Park III, Greater Noida - 201 306, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/amit.amit_66_22
|
|
|
Introduction: Zygomycetes consisting of Mucorales order is a group of fungal infections. These species cause life threatening opportunistic fungal infections mucormycosis. This infection is highly prevalent in immunocompromised. During the 2nd wave of Covid 19 pandemic corticosteroid treatment was used which has been linked to development of Mucormycosis. In our tertiary care teaching hospital we saw that patients suffering from Covid-19 infections developed mucormycosis. We present these cases in our study. To study the clinical, demographical,and Laboratory parameters in Covid-19 patients with Mucormycosis. Material and Methods: Retrospective Study. All biopsy proven cases of Mucormycosis (which developed after Covid-19 infection) were included. Relevant Clinical Demographics and Laboratory data was retrieved from the available case sheets. The data was tabulated in Excel sheet and further reviewed. Results: A total of 22 patients were diagnosed as suffering from mucormycosis majority were unvaccinated. 11 patients out of 22 (50%) started manifesting mucormycosis within one week of COVID infection. All the patients who had only single comorbidity (22.72%) suffered from mild disease and patient who had more than one comorbidity suffered from moderate (27.27%) to severe (50%) COVID infection. Conclusion: It is suggested that patients with Covid-19 infection are at risk for development of opportunistic fungal infections like Mucormycosis. Hence the physicians who are involved in treating such patients must be mindful of the fact that mucormycosis can develop in them. Histopathology helps in establishing a concrete diagnosis of Mucormycosis.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
